Showing 696 results
-
Media Release /
-
Media Release /• Data from FREEDOMS study show Gilenya reduced relapses in patients who discontinued another MS therapy due to side effects or inadequate efficacy• Analyses of five clinical studies show Gilenya,…
-
Media Release /
-
Media Release /- "Together in MS" partners professional cycling team members with people living with MS for Bike MS rides on tandem bicycles across the country- Phil Keoghan, MS advocate and TV host, rides tandem…
-
Media Release /
-
Media Release /• In the trial, patients on Exelon Patch 13.3 mg/24 h showed less functional decline vs. 9.5 mg/24 h patch in mild to moderate Alzheimer’s disease• Numerical trend toward cognitive efficacy was seen…
-
Media Release /
-
Media Release /Results from open label phase III extension and 7-year phase II extension studies show sustained low disease activity on clinical and MRI measures in patients continuing on Gilenya (fingolimod)…
-
Media Release /
-
Media Release /Prescribing information (PI) includes new patient selection parameters based on certain cardiovascular considerations to aid in identifying patients for GilenyaUpdated Gilenya prescribing information…
